Charles River Laboratories International, Inc. (NYSE:CRL) Receives $198.36 Consensus Target Price from Brokerages

Charles River Laboratories International, Inc. (NYSE:CRL) has been given an average rating of “Hold” by the sixteen ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and one has issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $198.36.

A number of brokerages recently issued reports on CRL. Bank of America lowered their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Barclays dropped their price target on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 18th. TD Cowen raised their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday, November 11th. JPMorgan Chase & Co. lowered their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. Finally, Citigroup raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and increased their target price for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th.

Insiders Place Their Bets

In other Charles River Laboratories International news, COO Birgit Girshick purchased 1,514 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the acquisition, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Charles River Laboratories International

A number of hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Charles River Laboratories International by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company’s stock worth $1,136,938,000 after buying an additional 60,497 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Charles River Laboratories International by 9.0% in the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company’s stock worth $752,508,000 after purchasing an additional 335,658 shares during the last quarter. State Street Corp raised its stake in shares of Charles River Laboratories International by 2.0% during the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after acquiring an additional 41,421 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Charles River Laboratories International by 2.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock valued at $330,231,000 after buying an additional 47,221 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Charles River Laboratories International by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company’s stock valued at $227,042,000 after purchasing an additional 14,787 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Down 0.4 %

Shares of NYSE:CRL opened at $175.13 on Tuesday. The firm has a market capitalization of $8.96 billion, a P/E ratio of 1,167.55, a P/E/G ratio of 4.54 and a beta of 1.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The stock has a 50 day moving average price of $168.99 and a 200-day moving average price of $185.45. Charles River Laboratories International has a 52-week low of $150.79 and a 52-week high of $274.77.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same quarter in the prior year, the company earned $2.46 earnings per share. The firm’s quarterly revenue was down 1.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).